Description: Cizzle Biotechnology Holdings Plc, together with its subsidiaries, develops an immunoassay test for the CIZ1B cancer biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Home Page: www.cizzlebiotechnology.com
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 20 3934 6630
Officers
| Name | Title |
|---|---|
| Dr. Allan John Syms | Executive Chairman |
| Prof. Dawn Coverley | Founder & Independent Non-Executive Director |
| Mr. Nigel R. Lee | Finance Director & Executive Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.0769 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |